The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty ...

US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of ...

Singapore-based biotech Hummingbird Bioscience has outlicensed its lead immunotherapy candidate, HMBD-002, to Australian drug ...

US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Australian biotech CSL Limited Europe-based subsidiary CSL Behring announced a milestone in the early benefit assessment of ...

Bayer’s (BAYN: DE) cell therapy subsidiary BlueRock Therapeutics is shifting its priorities, cutting around 50 jobs and ...

Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the ...

PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop ...

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (previously known as EG-70), Canadian company enGene’s lead ...